torvutatug samrotecan

Torvutatug samrotecan is an investigational **folate receptor alpha-targeted antibody-drug conjugate** being developed by AstraZeneca for solid tumors, particularly ovarian cancer and lung adenocarcinoma. It comprises torvutatug, a human monoclonal antibody directed against folate receptor alpha, linked via the samrotecan linker-payload system to **exatecan**, a topoisomerase I inhibitor payload. After binding FRalpha on tumor cells, the ADC is internalized and releases its cytotoxic payload intracellularly, leading to DNA damage and antitumor activity. Public sources identify ongoing development in ovarian cancer, including a Phase III trial in platinum-resistant ovarian cancer comparing AZD5335 with mirvetuximab soravtansine in patients with high or low FRalpha expression, as well as earlier-stage development in broader solid tumors and lung adenocarcinoma.

Other names

torvutatug samrotecan